Testing polatuzumab and chemotherapy with or without glofitamab
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 study tests combinations of anti-cancer drugs plus standard chemotherapy for people with newly diagnosed, aggressive large B-cell lymphoma. It aims to find safer dosing and better response options (with or without an added drug called glofitamab).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18+) with newly diagnosed aggressive large B-cell lymphoma that has higher-risk features
- You are planned to receive the full standard treatment plan of 6 chemotherapy cycles (DA-EPOCH-R or equivalent as your doctor chooses)
- Your cancer has to be measurable on scans (for example, certain lymph node or outside-the-node size targets on CT or PET-CT)
- Your body is strong enough for treatment: general health score (ECOG) must be 0–2, and key blood counts are high enough
- Your heart and organ tests must be strong enough (heart pumping strength and kidney/liver blood tests within limits)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, epcoritamab, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with aggressive B-cell non-Hodgkin lymphoma that hasn't been treated before or has had only one round of chemo. It aims to see if this combination works better against certain high-risk types of lymphoma.
This study tests a new drug called glofitamab combined with standard chemotherapy (RCHOP) for people with HIV who have been newly diagnosed with a type of blood cancer called large B-cell lymphoma. The goal is to see if adding glofitamab helps fight the cancer better than chemotherapy alone.
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
This trial tests a combination of three targeted drugs (tafasitamab, polatuzumab vedotin, and glofitamab) as a first treatment for diffuse large B-cell lymphoma or high-grade B-cell lymphoma. It aims to see if this approach can be effective without standard chemotherapy.
This trial tests a combination of three targeted drugs (glofitamab, polatuzumab vedotin, and zuberitamab) for people with newly diagnosed, aggressive B-cell lymphoma that hasn't been treated yet. The goal is to see if this combination works better than standard therapy.
This trial tests a combination of three drugs (G-Pola-ZLP) for people with newly diagnosed Diffuse Large B-Cell Lymphoma who have not had chemotherapy before. The goal is to see if this treatment works well and is safe.
Hear when a new Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.